Warner J, Whitmore W F
Urologic Service of Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
J Urol. 1994 Nov;152(5 Pt 2):1761-5. doi: 10.1016/s0022-5347(17)32380-7.
Among approximately 4,000 prostatic cancer registrations 75 patients with clinical stage B histologically proved prostatic cancer receiving no therapy for at least 1 year after diagnosis were identified and managed expectantly. Of the patients 29 had stage B1, 37 stage B2 and 9 stage B3 lesions. Eight patients ultimately elected definitive radiation treatment. First evidence of tumor progression was local in more than 90% of the cases. Overall median intervals were 78 months to local progression, 186 months to metastasis, 108 months to initiation of any treatment and 156 months to death. The rate of tumor progression was often consistent with protracted survival. Prostatic cancer and co-morbidity were each significant forces of mortality.
在大约4000例前列腺癌登记病例中，确定了75例经组织学证实为临床B期前列腺癌且诊断后至少1年未接受治疗的患者，并对其进行了观察性管理。这些患者中，29例为B1期，37例为B2期，9例为B3期病变。8例患者最终选择了确定性放疗。超过90%的病例中肿瘤进展的首个证据是局部性的。总体中位间隔时间为至局部进展78个月、至转移186个月、至开始任何治疗108个月以及至死亡156个月。肿瘤进展率通常与长期生存一致。前列腺癌和合并症都是导致死亡的重要因素。
